Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Endocrinol Metab (Seoul). 2015 Dec;30(4):475-80. doi: 10.3803/EnM.2015.30.4.475. Epub 2015 Sep 22.
Antithyroid drugs (ATDs) can lead to the development of agranulocytosis, which is the most serious adverse effect. Characteristics of ATD-induced agranulocytosis (AIA) have seldom been reported due to the rarity. In this study, we characterized the clinical features for AIA in Korean patients.
We retrospectively reviewed data from patients with AIA diagnosed between 1997 and 2014 at four tertiary hospitals. Agranulocytosis was defined as an absolute neutrophil count (ANC) below 500/mm³.
The mean age of the patients (11 males, 43 females) was 38.2±14.9 years. Forty-eight patients (88.9%) with AIA had fever and sore throat on initial presentation, 20.4% of patients developed AIA during the second course of treatment, and 75.9% of patients suffered AIA within 3 months after initiation of ATD. The patients taking methimazole (n=39) showed lower levels of ANC and more frequent use of granulocyte-macrophage colony-stimulating factor than propylthiouracil (n=15) users. The median duration of agranulocytosis was 5.5 days (range, 1 to 20). No differences were observed between the long (≥6 days) and short recovery time (≤5 days) groups in terms of age, gender, ATDs, duration of ATDs, or initial ANC levels. Four patients (7.4%) who were taking ATDs for less than 2 months died of sepsis on the first or second day of hospitalization.
The majority of AIA incidents occur in the early treatment period. Considering the high fatality rate of AIA, an early aggressive therapeutic approach is critical and patients should be well informed regarding the warning symptoms of the disease.
抗甲状腺药物(ATD)可导致粒细胞缺乏症的发生,这是最严重的不良反应。由于其罕见性,很少有报道描述 ATD 诱导的粒细胞缺乏症(AIA)的特征。在本研究中,我们对韩国患者 AIA 的临床特征进行了描述。
我们回顾性分析了 1997 年至 2014 年在四家三级医院诊断为 AIA 的患者数据。粒细胞缺乏症定义为绝对中性粒细胞计数(ANC)<500/mm³。
患者的平均年龄(11 名男性,43 名女性)为 38.2±14.9 岁。48 例(88.9%)AIA 患者初诊时有发热和咽痛,20.4%的患者在第二疗程中发生 AIA,75.9%的患者在开始 ATD 后 3 个月内发生 AIA。服用甲巯咪唑(n=39)的患者 ANC 水平较低,更频繁地使用粒细胞-巨噬细胞集落刺激因子,而丙基硫氧嘧啶(n=15)的患者则较少。粒细胞缺乏症的中位持续时间为 5.5 天(范围,1 至 20)。在年龄、性别、ATD、ATD 持续时间或初始 ANC 水平方面,无差异。4 名(7.4%)服用 ATD 不足 2 个月的患者在住院的第 1 或第 2 天因脓毒症死亡。
大多数 AIA 事件发生在早期治疗期间。鉴于 AIA 的高死亡率,早期积极的治疗方法至关重要,并且应向患者充分告知疾病的警告症状。